Compare AVAH & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVAH | NUVB |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | N/A | 307 |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2021 | N/A |
| Metric | AVAH | NUVB |
|---|---|---|
| Price | $8.52 | $5.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $9.75 | ★ $11.38 |
| AVG Volume (30 Days) | 1.8M | ★ 4.7M |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1850.00 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $2,433,199,000.00 | N/A |
| Revenue This Year | $7.31 | $203.82 |
| Revenue Next Year | $5.59 | $58.18 |
| P/E Ratio | $44.58 | ★ N/A |
| Revenue Growth | ★ 20.19 | N/A |
| 52 Week Low | $3.73 | $1.87 |
| 52 Week High | $10.32 | $9.75 |
| Indicator | AVAH | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 76.83 | 63.06 |
| Support Level | $7.77 | $4.13 |
| Resistance Level | $8.68 | $6.06 |
| Average True Range (ATR) | 0.30 | 0.41 |
| MACD | 0.16 | 0.13 |
| Stochastic Oscillator | 94.71 | 69.07 |
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). The Private Duty Services segment generates the majority of revenue, which includes private duty skilled nursing services, non-clinical and personal care services, and pediatric therapy services, and is principally reimbursed by Medicaid and Medicaid MCO.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.